CAJ | 학술논문

目的评价伊立替康(CPT-11)联合氟尿嘧啶(5-FU)治疗晚期直肠癌的临床疗效及毒副作用.方法选择晚期直肠癌患者86例,根据给药方式的不同将患者随机分为FOLFIRI治疗组和IFL治疗组.通过CR、PR、SD及RR等指标观察临床疗效,通过骨髓抑制、消化道反应及静脉炎等指标观察毒副作用.结果 FOLFIRI治疗组和IFL治疗组在CR、PR、SD及RR等临床疗效方面差异无统计学意义(均P＞0.05),在骨髓抑制、消化道反应及静脉炎等毒副作用方面差异也无统计学意义(均P＞0.05).结论伊立替康联合5-FU治疗晚期直肠癌疗效较好,毒副作用较少.
목적 평개이립체강(CPT-11)연합불뇨밀정(5-FU)치료만기직장암적림상료효급독부작용.방법 선택만기직장암환자86례,근거급약방식적불동장환자수궤분위FOLFIRI치료조화IFL치료조.통과CR、PR、SD급RR등지표관찰림상료효,통과골수억제、소화도반응급정맥염등지표관찰독부작용.결과 FOLFIRI치료조화IFL치료조재CR、PR、SD급RR등림상료효방면차이무통계학의의(균P＞0.05),재골수억제、소화도반응급정맥염등독부작용방면차이야무통계학의의(균P＞0.05).결론 이립체강연합5-FU치료만기직장암료효교호,독부작용교소.
Objective To evaluate the efficacy and adverse events of irinotecan (CPT-11) combined with 5-FU in treatment of patients with advanced rectal cancer. Methods 86 patients were randomly divided into FOLFIRI treatment group and IFL treatment group. The efficacy and adverse events were observed. Results There was no statistically significant difference between FOLFIRI treatment group and IFL treatment group in CR、PR、SD and RR(all P ＞ 0. 05). There was also no statistically significant difference between FOLFIRI treatment group and IFL treatment group in adverse events(all P ＞ 0.05). Conclusion Irinotecan in combination with 5-FU was effective and had some tolerable adverse events in treating patients with advanced rectal cancer in both FOLFIRI treatment group and IFL treatment group.